Effects of cardioselective and non-cardioselective beta-blockade on adrenaline-induced metabolic and cardiovascular responses in man.
In 12 normal volunteers the interaction between the metabolic and cardiovascular effects of adrenaline and either a cardioselective (atenolol 150 mg p. o. for 1 week) or a non-selective beta-blocker with intrinsic sympathomimetic activity (pindolol 15 mg p. o. for 1 week) were studied. Equiactive doses of the beta-blockers were investigated with respect to their metabolic effects. There were profound differences in the metabolic profile of the two substances: the non-cardioselective beta-blocker caused significant inhibition of the lipolytic, glycogenolytic and the growth hormone-releasing effects of adrenaline when compared to the cardioselective agent. The results indicate that, during non-cardioselective beta-blockade, metabolic effects occur which should favourably influence myocardial oxygen consumption by making myocardial performance more economical.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000328:Adult; D001262:Atenolol / Q000494:pharmacology; D001786:Blood Glucose / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D004837:Epinephrine / Q000494:pharmacology*; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D013006:Growth Hormone / Q000378:metabolism*; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D010101:Oxygen Consumption / Q000187:drug effects; D010869:Pindolol / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D001262:Atenolol; D013006:Growth Hormone; D010869:Pindolol; D004837:Epinephrine